More support for the
Her2/ER crosstalk concept.
The really interesting aspect (missing from the discussion) of this is that there is more than a suggestion that the actual ER and Her2 status can essentially change after extended therapy. So..someone with a Her2+/ER- biopsy may get benefit from ER therapies after the Herceptin and/or Tykerb therapies "upregulate" the ER side.
The other more obvious bit here is that
Fulvestrant needs to be made available in adjuvant.
(Psst! Green tea is thought to inhibit both Her2 and ER)